Premium
A clinical study of low molecular weight‐hydroxyethyl starch, a new plasma expander.
Author(s) -
Mishler JM,
Parry ES,
Sutherland BA,
Bushrod JR
Publication year - 1979
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1979.tb04652.x
Subject(s) - hydroxyethyl starch , pharmacokinetics , hetastarch , urine , plasma volume , intravascular volume status , chemistry , medicine , urology , anesthesia , endocrinology , hemodynamics
1. The pharmacokinetics of a new plasma expander, low molecular weight‐ hydroxyethyl starch (LMW‐HES) were examined in six normovolaemic men. 2. One hour post‐infusion, 13.5% of the total dose of LMW‐HES injected was excreted in the urine, 50.2% was present in the intravascular space, and 36.3% was unaccounted for. 3. Twenty‐four hours post‐ infusion, 65.5% of the total dose of injected LMW‐HES had been excreted in the urine, 4.1% remained intravascularly, and 30.4% was unaccounted for. 4. The plasma volume increased rapidly from a mean value of 45.7 ml kg‐1 to a maximum value of 57.9 ml kg‐1 immediately post‐injection, then gradually returned to normal over 24 h. 5. The infusion of an average of 58.1 g had no effect on ESR, renal and hepatic biochemical indices. 6. LMW‐HES appears to be safe and effective, and should be of value clinically when rapid and short‐lived augmentation of the plasma volume is required.